Allogene Therapeutics (ALLO) Cash from Financing Activities (2018 - 2026)

Allogene Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $21.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 50.98% year-over-year to $21.1 million; the TTM figure through Mar 2026 stood at $37.3 million (down 71.1% YoY), while the FY2025 annual figure was $30.2 million, down 74.15% from the prior year.
• Cash from Financing Activities came in at $21.1 million for Q1 2026 at Allogene Therapeutics, up from $7.9 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $108.6 million in Q2 2024 to a low of $24000.0 in Q2 2022.
• A 5-year average of $15.7 million and a median of $3.2 million in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 99.25% in 2022 and surged 372916.67% in 2023, its largest moves.
• Allogene Therapeutics' Cash from Financing Activities stood at $46000.0 in 2022, then soared by 236.96% to $155000.0 in 2023, then surged by 3605.16% to $5.7 million in 2024, then jumped by 36.84% to $7.9 million in 2025, then soared by 168.76% to $21.1 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $21.1 million, $7.9 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison